4 analysts have expressed a variety of opinions on MiMedx Group (NASDAQ:MDXG) over the past quarter, offering a diverse set of opinions from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.5, a high estimate of $10.00, and a low estimate of $8.00. This current average represents a 20.83% decrease from the previous average price target of $12.00.

Investigating Analyst Ratings: An Elaborate Study

The analysis of recent analyst actions sheds light on the perception of MiMedx Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to MiMedx Group. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of MiMedx Group compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of MiMedx Group's stock. This examination reveals shifts in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of MiMedx Group's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on MiMedx Group analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About MiMedx Group

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

MiMedx Group: A Financial Overview

Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.

Revenue Growth: MiMedx Group's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 35.3%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: MiMedx Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.73% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): MiMedx Group's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.35% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): MiMedx Group's ROA excels beyond industry benchmarks, reaching 5.49%. This signifies efficient management of assets and strong financial health.

Debt Management: MiMedx Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.08.

How Are Analyst Ratings Determined?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.